AKT1 is altered in 0.37% of cholangiocarcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AKT2 is altered in 0.33% of cholangiocarcinoma patients [2].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AKT3 is altered in 1.12% of cholangiocarcinoma patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 1.51% of cholangiocarcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

APH1A is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains APH1A status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

APOBEC3A is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3A status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

APOBEC3B is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3B status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

APOBEC3C is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3C status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

APOBEC3D is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3D status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

APOBEC3G is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3G status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

APOBEC3H is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3H status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ARID1A is altered in 17.68% of cholangiocarcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is altered in 5.83% of cholangiocarcinoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR is altered in 2.24% of cholangiocarcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATRX is altered in 2.21% of cholangiocarcinoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is altered in 1.13% of cholangiocarcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 5.02% of cholangiocarcinoma patients [2].

BRAF is an inclusion eligibility criterion in 3 clinical trials for cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

Dabrafenib and trametinib have evidence of efficacy in patients with BRAF mutation in cholangiocarcinoma [3].

BRCA1 is altered in 1.73% of cholangiocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 is altered in 3.87% of cholangiocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRIP1 is altered in 0.68% of cholangiocarcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

C11orf30 is altered in 0.22% of cholangiocarcinoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 2.23% of cholangiocarcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 14.62% of cholangiocarcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2B is altered in 10.07% of cholangiocarcinoma patients [2].

CDKN2B is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2B status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK1 is altered in 0.48% of cholangiocarcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is altered in 0.45% of cholangiocarcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DLL4 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EGFR is altered in 2.41% of cholangiocarcinoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 4.07% of cholangiocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ERCC2 is altered in 1.33% of cholangiocarcinoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC3 is altered in 1.14% of cholangiocarcinoma patients [2].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC4 is altered in 0.88% of cholangiocarcinoma patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC5 is altered in 1.13% of cholangiocarcinoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is altered in 1.99% of cholangiocarcinoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCB is altered in 1.0% of cholangiocarcinoma patients [2].

FANCB is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCC is altered in 0.23% of cholangiocarcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCD2 is altered in 3.7% of cholangiocarcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCE is altered in 1.44% of cholangiocarcinoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCF is altered in 0.72% of cholangiocarcinoma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCG is altered in 1.38% of cholangiocarcinoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCL is altered in 0.94% of cholangiocarcinoma patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCM is altered in 5.0% of cholangiocarcinoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FBXW7 is altered in 1.99% of cholangiocarcinoma patients [2].

FBXW7 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FBXW7 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGF1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF10 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF10 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF11 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF11 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF12 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF12 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF13 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF13 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF14 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF14 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF16 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF16 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF17 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF17 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF18 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF18 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF19 is altered in 3.0% of cholangiocarcinoma patients [2].

FGF19 is an inclusion eligibility criterion in 2 clinical trials for cholangiocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGF19 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FGF2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF20 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF20 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF21 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF21 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF22 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF22 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF23 is altered in 1.0% of cholangiocarcinoma patients [2].

FGF23 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF23 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF3 is altered in 3.14% of cholangiocarcinoma patients [2].

FGF3 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF4 is altered in 2.91% of cholangiocarcinoma patients [2].

FGF4 is an inclusion eligibility criterion in 2 clinical trials for cholangiocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGF4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FGF5 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF6 is altered in 1.98% of cholangiocarcinoma patients [2].

FGF6 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF7 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF7 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF8 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF8 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is altered in 0.68% of cholangiocarcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 6 clinical trials for cholangiocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain FGFR1 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FGFR2 is altered in 10.72% of cholangiocarcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 10 clinical trials for cholangiocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain FGFR2 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open) [3].

Infigratinib and pemigatinib have evidence of efficacy in patients with FGFR2 mutation in cholangiocarcinoma [3].

FGFR3 is altered in 2.17% of cholangiocarcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 6 clinical trials for cholangiocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain FGFR3 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FGFR4 is altered in 1.11% of cholangiocarcinoma patients [2].

FGFR4 is an inclusion eligibility criterion in 4 clinical trials for cholangiocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain FGFR4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is altered in 0.09% of cholangiocarcinoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH1 is altered in 15.57% of cholangiocarcinoma patients [2].

IDH1 is an inclusion eligibility criterion in 6 clinical trials for cholangiocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain IDH1 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

Ivosidenib has evidence of efficacy in patients with IDH1 mutation in cholangiocarcinoma [3].

IDH2 is altered in 3.57% of cholangiocarcinoma patients [2].

IDH2 is an inclusion eligibility criterion in 3 clinical trials for cholangiocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain IDH2 status and cholangiocarcinoma as inclusion criteria, 3 are phase 2 (2 open) [3].

JAG1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains JAG1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is altered in 1.12% of cholangiocarcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is altered in 18.96% of cholangiocarcinoma patients [2].

KRAS is an inclusion eligibility criterion in 3 clinical trials for cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

MAML1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAML1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAP2K1 is altered in 0.8% of cholangiocarcinoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K2 is altered in 0.46% of cholangiocarcinoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K3 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K4 is altered in 1.23% of cholangiocarcinoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K5 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K5 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K6 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K6 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K7 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K7 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK1 is altered in 0.74% of cholangiocarcinoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK3 is altered in 0.74% of cholangiocarcinoma patients [2].

MAPK3 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM2 is altered in 4.45% of cholangiocarcinoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM4 is altered in 1.13% of cholangiocarcinoma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET is altered in 1.7% of cholangiocarcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH1 is altered in 1.01% of cholangiocarcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 is altered in 2.84% of cholangiocarcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 0.48% of cholangiocarcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is altered in 1.07% of cholangiocarcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH3 is altered in 0.99% of cholangiocarcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 1.99% of cholangiocarcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MUTYH is altered in 0.57% of cholangiocarcinoma patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is altered in 1.44% of cholangiocarcinoma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NCSTN is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NCSTN status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH1 is altered in 1.14% of cholangiocarcinoma patients [2].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH2 is altered in 2.22% of cholangiocarcinoma patients [2].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH3 is altered in 1.88% of cholangiocarcinoma patients [2].

NOTCH3 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH4 is altered in 1.76% of cholangiocarcinoma patients [2].

NOTCH4 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1 is altered in 0.22% of cholangiocarcinoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is altered in 3.19% of cholangiocarcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PALB2 is altered in 1.61% of cholangiocarcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PARP1 is altered in 1.1% of cholangiocarcinoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 0.75% of cholangiocarcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is altered in 5.01% of cholangiocarcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 is altered in 0.74% of cholangiocarcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 0.8% of cholangiocarcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 2.75% of cholangiocarcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPP2R1A is altered in 0.98% of cholangiocarcinoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is altered in 1.96% of cholangiocarcinoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD50 is altered in 1.09% of cholangiocarcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51 is altered in 0.11% of cholangiocarcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is altered in 0.77% of cholangiocarcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51D is altered in 0.54% of cholangiocarcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD54L is altered in 0.48% of cholangiocarcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is altered in 2.01% of cholangiocarcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SMARCB1 is altered in 0.78% of cholangiocarcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is altered in 1.24% of cholangiocarcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STK11 is altered in 2.73% of cholangiocarcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 26.66% of cholangiocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains UGT1A1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

XRCC1 is altered in 1.0% of cholangiocarcinoma patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].